EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

# Curriculum Vitae

## Personal information

Per Albertsson

## Work experience

1. Employer: Swedish Medical products agency
   - Start date: 022023
   - End date:
   - Position: Analysist
   - Activities: Clinical Efficacy and Safety
   - Country: Sweden
2. Employer: Sahlgrenska University Hospital, Gothenburg
   - Start date: 082010
   - End date: 012023
   - Position: Chief physician, oncology
   - Activities: Oncologist, Radiation therapy. Research activities; alpha particle radioimmunotherapy; ovarian cancer, Breast cancer. Preclinical research, epidemiology
   - Country: Sweden
3. Employer: AprilBiotech AB
   - Start date: 180102
   - End date: 230101
   - Position: Stockowner, researcher
   - Activities: preclinical devlopment of 211At-trastuzumab and 211At-farletuzumab
   - Country: Sweden
4. Employer: Rigshospitalet, Copenhagen, The Finsen Center
   - Start date: 102007
   - End date: 062010
   - Position: Chief physician, radiation oncology
   - Activities: Oncologist, Radiation therapy.
   - Country: Denmark
5. Employer: Sahlgrenska University Hospital, Gothenburg
   - Start date: 052006
   - End date: 092007
   - Position: Chief physician, oncology
   - Activities: Medical Oncologist, Gastrointestinal Cancer
   - Country: Sweden
6. Employer: Aalborg Hospital, Aarhus University Hospital
   - Start date: 102005
   - End date: 042006
   - Position: Chief physician, oncology
   - Activities: Medical Oncologist, Gastroinestinal cancer
   - Country: Denmark
7. Employer: Sahlgrenska University Hospital, Gothenburg
   - Start date: 052003
   - End date: 092005
   - Position: Oncologist (specialist physician)
   - Activities: Radiation Therapy
   - Country: Sweden

## Education and training

1. Subject: University of Gothenburg
   - Start date: 122000
   - End date: 092005
   - Qualification: Assoc. Professor
   - Organisation:
   - Country: Sweden
2. Subject: Sahlgrenska University Hospital, Gothenburg
   - Start date: 011997
   - End date: 052003
   - Qualification: Resident Oncology
   - Organisation: Medical Oncology and radiation therapy
   - Country: Sweden
3. Subject: University of Gothenburg
   - Start date: 081996
   - End date: 112000
   - Qualification: PhD
   - Organisation: PhD, subject: Anatomy and CellBiology Thesis Title: ”Matrix Metalloproteinases in Natural Killer Cells. Expression of MMPs, IL_2 activation, and killer cell interactions with Matrigel® and model tumours”
   - Country: Sweden
4. Subject: University of Gothenburg
   - Start date: 011989
   - End date: 051994
   - Qualification: Medical Degree
   - Organisation:

- Country: Sweden

## Additional information

### Publications

In Total 84 Publications (excluding conference abstracts etc.) _original articles, peer reviewed (70) _review articles, _peer reviewed (3) _miscellaneous scientific publications (11) Original (peer reviewed) articles by area: a) Targeted alpha therapy: 24 articles (2 clinical status reviews, 3 tolerability/ secondary cancer investigations, 9 preclinical /in vivo investigations, 2 biokinetic modelling articles, 8 chemistry/ labelling studies). b) Ovarian cancer: 4 articles mainly epidemiological (survival, surgical complications and cost of illness, IHC) c) Breast cancer: 3 epidemiological studies, (survival; _radiotherapy, _histology, _age/stage) d) Imaging 3: (2 PET_CT, 1 MRI) e) Clinical Radiation therapy and/or chemotherapy: 5 (4 cohort studies) f) Radiobiology: 3 g) Immunology: 16. (NK_cell biology 3, Lymphocyte tumour infiltration/ matrixdegradation 13) h) Chemotherapy: 12 (preclinical antiangiogenesis/metronomic chemo 8, pharmacogenomic retrospective cohort/case report 2, misc. 2) 1. Albertsson P*, Bäck TA, Bergmark K, Hallqvist A, Johansson M, Aneheim E, Lindegren L, Timperanza C, Smerud K and Palm S _Astatine_211 based radionuclide therapy: Current clinical trial landscape Frontiers in Medicine, Section Nuclear Medicine, doi: 10.3389/fmed.2022.1076210 2. Palmqvist C, Persson J, Albertsson P, Dahm_Kähler P, Johansson M. _Societal costs of ovarian cancer in a population_based cohort _ a cost of illness analysis. Acta Oncol. 2022 Nov;61(11):1369_1376. doi: 10.1080/0284186X.2022.2140015. 3. Leidermark E, Hallqvist A, Jacobsson L, Karlsson P, Holmberg E, Bäck T, Johansson M, Lindegren S, Palm S, Albertsson P. _Estimating the risk for secondary cancer following targeted alpha therapy with astatine_211 intraperitoneal radioimmunotherapy. J Nucl Med. 2022 Jul 7:jnumed.121.263349. doi: 10.2967/jnumed.121.263349. PMID: 35798559 4. Palmqvist C, Michaëlsson H, Staf C, Johansson M, Albertsson P, Dahm_Kähler P. _Complications after advanced ovarian cancer surgery_A population_based cohort study. Acta Obstet Gynecol Scand. 2022 Apr 11. doi: 10.1111/aogs.14355. Epub ahead of print 5. Chamalidou C, Fohlin H, Albertsson P, Arnesson LG, Einbeigi Z, Holmberg E, Nordenskjöld A, Nordenskjöld B, Karlsson P, Linderholm B; Swedish western and south_eastern breast cancer groups. Survival patterns of invasive lobular and invasive ductal breast cancer in a large population_based cohort with two decades of follow up. Breast. 2021 Oct;59:294_300. doi: 10.1016/j.breast.2021.07.011. Epub 2021 Jul 22. 6. Palmqvist C, Staf C, Mateoiu C, Johansson M, Albertsson P, Dahm_Kähler P. _Increased disease_free and relative survival in advanced ovarian cancer after centralized primary treatment. Gynecol Oncol. 2020 Nov;159(2):409_417. doi: 10.1016/j.ygyno.2020.09.004. 7. Palm S, Bäck T, Aneheim E, Hallqvist H, Hultborn R, Lars Jacobsson L, Jensen H, Lindegren S, Albertsson P. _Evaluation of therapeutic efficacy of 211At_labelled farletuzumab in a intraperitoneal mouse model of disseminated ovarian cancer Transl Oncol. 2021 Jan;14(1):100873. doi: 10.1016/j.tranon.2020.100873. Epub 2020 Sep 25. 8. Lindegren S, Albertsson P, Bäck T, Jensen H, Palm S, Aneheim E. _Realizing clinical trials with astatine_211: The chemistry infrastructure. Cancer Biother Radiopharm. 2020 Aug;35(6):425_436. doi: 10.1089/cbr.2019.3055 9. Bäck TA, Jennbacken K, Hagberg Thulin M, Lindegren S, Jensen H, Olafsen T, Yazaki PJ, Palm S, Albertsson P, Damber JE, Wu AM, Welén K. _Targeted alpha therapy with astatine_211_labeled anti_PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors. EJNMMI Res. 2020 Feb 11;10(1):10. doi: 10.1186/s13550_020_0600_z. 10. Aneheim E, Palm S, Jensen H, Ekberg C, Albertsson P, Lindegren S. _Towards elucidating the radiochemistry of astatine _ Behavior in chloroform. Sci Rep. 2019 Nov 4;9(1):15900. 11. Dekempeneer Y, Bäck T, Aneheim E, Jensen H, Puttemans J, Xavier C, Keyaerts M, Palm S, Albertsson P, Lahoutte T, Caveliers V, Lindegren S, D'Huyvetter M. _Labeling of anti_HER2 nanobodies with astatine_211: Optimization and the effect of different coupling reagents on their in vivo behavior. Mol Pharm. 2019 Aug 5;16(8):3524_3533. 12. Hultborn R, Albertsson P, Ottosson S, Warnhammar E, Palm Å, Palm S, Elmroth K. _Radiosensitivity: Gender and order of administration of G_CSF, An experimental study in mice. Radiat Res. 2019 Apr;191(4):335_341. 13. Hallqvist A, Bergmark K, Bäck TA, Andersson H, Dahm_Kähler P, Johansson M, Lindegren S, Jensen H, Jacobsson L, Hultborn R, Palm S, Albertsson P. _Intraperitoneal alpha_emitting radio immunotherapy with Astatine_211 in relapsed ovarian cancer; long_term follow_up with individual absorbed dose estimations. J Nucl Med. 2019 Aug;60(8):1073_1079. 14. Anna E. Nordenskjöld*, Helena. Fohlin*, Lars G. Arnesson, Zakaria Einbeigi, Erik Holmberg, Per Albertsson** and Per Karlsson** and the Swedish western and southeastern breast cancer groups. *contributed equally, **contributed equally _Breast cancer survival trends in different stages and age groups – a population based study 1989_2013 ACTA Oncologica. 2019 Jan;58(1):45_51 15. Albertsson P, Alverbratt C, Liljegren A, Björkander E, Strandell A, Samuelsson O, Palm S, Hallqvist A. _Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta_analysis. Crit Rev Oncol Hematol. 2018 Jun;126:6_12. 16. Nyholm T, Svensson S, Andersson S, Jonsson J, Sohlin M, Gustafsson C, Kjellén E, Söderström K, Albertsson P, Blomqvist L, Zackrisson B, Olsson LE, Gunnlaugsson A _MR and CT data with multi observer delineations of organs in the pelvic area _ part of the Gold Atlas project. Med Phys. 2018 Mar;45(3):1295_1300 17. Palm S, Back TA, Lindegren S, Hultborn R, Jacobsson L, Albertsson P. _Model of intraperitoneal targeted alpha_particle therapy shows post_therapy cold antibody boost (PT_CAB) enhances microtumor radiation dose and treatable tumor sizes. J Nucl Med. 2018 Apr;59(4):646_651. 18. Levan K, Mehryar M, Mateoiu C, Albertsson P, Bäck T, Sundfeldt K. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer. 2017 May 2;17(1):303. 19. Gustafsson_Lutz A, Bäck T, Aneheim E, Hultborn R, Palm S, Jacobsson L, Morgenstern A, Bruchertseifer F, Albertsson P and Lindegren S. _Therapeutic efficacy of α_radioimmunotherapy with different activity levels of the (213)Bi_labeled monoclonal antibody MX35 in an ovarian cancer model. EJNMMI Res. 2017 Dec;7(1):38. 20. Hallqvist A, Alverbratt C, Strandell A, Samuelsson O, Björkander E, Liljegren A, Albertsson P. _Positron emission tomography and computed tomographic imaging (PET/CT) for dose planning purposes of thoracic radiation with curative intent in lung cancer patients: A systematic review and meta_analysis. Radiother Oncol. 2017 Apr;123(1):71_77 21. Hultborn R, Sand J, Kinhult S, Lundgren L, Stierner U, Turesson I, Albertsson P. _Accelerated or conventional whole brain irradiation of malignant melanoma. Acta Oncol. 2017 Jul;56(7):1021_1023. 22. Bäck T, Chouin N, Lindegren S, Kahu H, Jensen H, Albertsson P and Palm S. _Cure of human ovarian carcinoma solid xenografts by fractionated α_radioimmunotherapy with (211)At_MX35_F(ab')(2): Influence of absorbed tumor dose and effect on long_term survival. J Nucl Med. 2017 Apr;58(4):598_604. 23. Anna Gustafsson_Lutz, Tom Bäck, Emma Aneheim, Stig Palm, Alfred Morgenstern, Frank Bruchertseifer, Per Albertsson, Sture Lindegren. _Biotinylated and chelated poly_L_lysine as an effector for pretargeting in cancer therapy and imaging. Int J Pharm Pharm Sci 2017;9(1):87_93. 24. Tomin K, Goldfarb RH, Albertsson P. _In vitro assessment of human Natural Killer cell migration and invasion. Methods Mol Biol. 2016;1441:65_74. 25. Aneheim E, Gustafsson A, Albertsson P, Ba¨**ck T, Jensen H, Palm S, Svedhem S, Lindegren S _Synthesis and evaluation of astatinated N**-[2_(Maleimido)ethyl]_3_ (trimethylstannyl) benzamide immunoconjugates. Bioconjugate Chem, 2016; 27:688–697 26. Palm S, Bäck T, Haraldsson B, Jacobsson L, Lindegren S, Albertsson P. Biokinetic modeling and dosimetry for optimizing intraperitoneal radioimmuno_therapy of ovarian cancer microtumors J Nucl Med, 2016; 57:594_600 27. Cederkrantz E, Andersson H, Bernhardt P, Bäck T, Hultborn R, Jacobsson L, Jensen H, Lindegren S, Ljungberg M, Magnander T, Palm S, Albertsson P. _Absorbed Doses and Risk Estimates of (211)At_MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients. Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):569_76. 28. Aneheim E, Albertsson P, Bäck T, Jensen H, Palm S, Lindegren S. _Automated astatination of biomoleculesa stepping stone towards multicenter clinical trials. Sci Rep. 2015 Jul 14;5:12025. 29. Nordenskjöld AE, Fohlin H, Albertsson P, Arnesson LG, Chamalidou C, Einbeigi Z, Holmberg E, Nordenskjöld B, Karlsson P; Swedish Western and Southeastern Breast Cancer Groups. _No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population_based study. Ann Oncol. 2015 Jun;26(6):1149_54. 30. Lindegren S, Andrade LN, Bäck T, Machado CM, Horta BB, Buchpiguel C, Moro AM, Okamoto OK, Jacobsson L, Cederkrantz E, Washiyama K, Aneheim E, Palm S, Jensen H, Tuma MC, Chammas R, Hultborn R, Albertsson P. _Binding affinity, specificity and comparative biodistribution of the parental murine monoclonal antibody MX35 (Anti_NaPi2b) and its humanized version Rebmab200. PLoS One. 2015 May 13;10(5):e0126298. 31. Aneheim E, Halleröd J, Albertsson P, Jensen H, Holgersson S, Lindegren S. _Shelf_life of ε_lysyl_3_(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies Cancer Biother Radiopharm. 2015 Feb;30(1):41_5. 32. Aneheim, E., Jensen, H., Albertsson, P.

Lindegren S. Astatine_211 labeling: a study towards automatic production of astatinated antibodies J Radioanal Nucl Chem (2015) 303: 979_983 https://doi.org/10.1007/s10967_014_3561_8 33. Lennernäs B, Majumder K, Damber JE, Albertsson P, Holmberg E, Brandberg Y, Isacsson U, Gunilla Ljung G, Damm O and Nilsson S. _Radical prostatectomy versus high_dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial of patient reported outcomes Acta Oncol. 2015 Jun;54(6):875_81. 34. Elgqvist J, Frost S, Pouget JP, Albertsson P. _The potential and hurdles of targeted alpha therapy _ clinical trials and beyond. Front Oncol. 2014 Jan 14;3:324. doi: 10.3389/fonc.2013.00324. 2014 Jan 14. Review. 35. Chouin N, Lindegren S, Frost SHL, Jensen H, Albertsson P, Hultborn R, Palm S, Jacobsson L and Bäck T _Ex vivo activity quantification in micrometastases at the cellular scale using the α_camera technique. J Nucl Med. 2013 Aug;54(8):1347_53 36. Frost S, Back T, Chouin N, Jensen H, Elgqvist J, Hultborn R, Jacobson L, Albertsson P and Lindegren S. _Comparison of 211At_PRIT and 211At_RIT of ovarian microtumors in a nude mouse model. Cancer Biother Radiopharm. 2013 28(2):108_14. 37. Chouin N, Lindegren S, Jensen H, Albertsson P and Bäck T. _Quantification of activity by alpha_camera imaging and small_scale dosimetry within ovarian carcinoma micrometastases treated with targeted alpha therapy. Q J Nucl Med Mol Imaging. 2012 56(6):487_95 38. Holländer C, Baeksgaard L, Sorensen M, Albertsson P, Damstrup L and Lassen U. _A phase I trial of concomitant radiotherapy and Oxaliplatin, tegafur/Uracil and Cetuximab as first_line therapy for locally advanced oesophageal cancer. Anticancer Res. 2012: 32(9):4019_23. 39. Gustafsson AM, Bäck T, Elgqvist J, Jacobsson L, Hultborn R, Albertsson P, Morgenstern A, Bruchertseifer F, Jensen H, Lindegren S. _Comparison of therapeutic efficacy and biodistribution of 213Bi_ and 211At_labeled monoclonal antibody MX35 in an ovarian cancer model. Nucl Med Biol. 2011 Sep 27 40. Albertsson P, Lennernas B and Norrby K. _On continuous chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF_A_mediated angiogenesis. APMIS. 2012 Feb;120(2):147_56 41. Edsparr K, Basse PH, Goldfarb RH, Albertsson P. _Matrix metalloproteinases in cytotoxic lymphocytes impact on tumour infiltration and immunomodulation. Cancer Microenviron. 2011: 4(3):351_60 42. Jellvert A, Franck_Lissbrant I, Edgren M, Ovferholm E, Braide K, Ekelund_Olvenmark AM, Kindblom J, Albertsson P and Lennernas B. _Effective low_toxicity oral combination metronomic chemotherapy with low toxicity for the management of castration_resistant prostate cancer. Experimental and Therapeutic Medicine 2: 579_584, 2011 43. Novotny A, Edsparr K, Nylund G, Khorram_Manesh A, Albertsson P, Nordgren S, Delbro DS. _A pharmacological analysis of the cholinergic regulation of urokinase_type plasminogen activator secretion in the human colon cancer cell line, HT_29. Eur J Pharmacol. 2010 10;646(1_3):22_30. 44. Edsparr K, Speetjens FM, Mulder_Stapel A, Goldfarb RH, Basse PH, Lennernäs B, Kuppen PJ, Albertsson P. _Effects of IL_2 on MMP expression in freshly isolated human NK cells and the IL_2_independent NK cell line YT. J Immunother. 2010 Jun;33(5):475_81. 45. Ofverholm A, Arkblad E, Skrtic S, Albertsson P, Shubbar E, Enerbäck C. _Two cases of 5_fluorouracil toxicity linked with gene variants in the DPYD gene. Clin Biochem. 2010 Feb;43(3):331_4. 46. Ofverholm A, Einbeigi Z, Manouchehrpour S, Albertsson P, Skrtic S, Enerbäck C _The ABCB1 3435 T allele does not increase the risk of paclitaxel_induced neurotoxicity. Oncology Letters 2010 Jan;1(1): 151_154. 47. Edsparr K, Johansson BR, Goldfarb RH, Basse PH, Nannmark U, Speetjens FM, Kuppen PJ, Lennernäs B, Albertsson P. _Human NK cell lines migrate differentially in vitro related to matrix interaction and MMP expression. Immunol Cell Biol. 2009; 87(6):489_95. 48. Albertsson P, Lennernäs B, Norrby K. _Low_dose continuous 5_fluorouracil infusion stimulates VEGF_A_mediated angiogenesis. Acta Oncol. 2009;48(3):418_25. 49. Albertsson P, Lennernäs B, Norrby K. _Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF_A. Acta Oncol. 2008;47(2):293_300. 50. Lennernäs B, Albertsson P, Edgren M, Nilsson S. _Calculated and simulated effects of heterogeneous dose distributions in radiotherapy using the dose volume inhomogeneity corrected biological equivalent dose formula with special reference to prostate cancer. Oncol Rep. 2007 Nov;18(5):1299_303 51. Albertsson P, Basse PH, Edsparr K, Kim MH, Goldfarb RH, Kitson RP, Lennernäs B, Nannmark U, Johansson BR. _Differential locomotion of long_ and short_term IL_2_activated murine natural killer cells in a model matrix environment. Scand J Immunol. 2007 Oct;66(4):402_9. 52. Edgren M, Ekelund AM, Albertsson P, Lundberg LM, Ullen A, Levitt S, Nilsson S, Lennernäs B. _High dose_rate brachytherapy of prostate cancer utilizing Iridium_192 after_loading technique: technical and methodological aspects. Int J Oncol. 2006;29(6):1517_24. 53. Albertsson P, Lennernäs B, Norrby K. _On metronomic chemotherapy: modulation of angiogenesis mediated by VEGF_A. Acta Oncol. 2006;45(2):144_55. 54. Damber JE, Vallbo C, Albertsson P, Lennernäs B, Norrby K. _The anti_tumour effect of low_dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol. 2006 Sep;58(3):354_60. 55. Yang Q, Goding S, Hagenaars M, Carlos T, Albertsson P, Kuppen P, Nannmark U, Hokland ME, Basse PH. _Morphological appearance, content of extracellular matrix and vascular density of lung metastases predicts permissiveness to infiltration by adoptively transferred natural killer and T cells. Cancer Immunol Immunother. 2006 Jun;55(6):699_707. 56. Sandel MH, Speetjens FM, Menon AG, Albertsson PA, Basse PH, Hokland M, Nagelkerke JF, Tollenaar RA, van de Velde CJ, Kuppen PJ. _Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol. 2005 Feb;42(4):541_6. 57. Lennernäs B, Sandberg D, Albertsson P, Silén A, Isacsson U. _The effectiveness of artificial neural networks in evaluating treatment plans for patients requiring external beam radiotherapy. Oncol Rep. 2004 Nov;12(5):1065_70. 58. Lennernäs B, Albertsson P, Damber JE, Norrby K. _Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non_tumor tissue in the same animals: a quantitative study. APMIS. 2004 Mar;112(3):201_9. 59. Albertsson P, Lennernäs B, Norrby K. _Chemotherapy and antiangiogenesis: drug_specific effects on microvessel sprouting. APMIS. 2003 Nov;111(11):995_1003. 60. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ. _NK cells and the tumour microenvironment: implications for NK_cell function and anti_tumour activity. Trends Immunol. 2003 Nov;24(11):603_9. 61. Lennernäs B, Albertsson P, Lennernäs H, Norrby K. _Chemotherapy and antiangiogenesisdrug_specific, dose_related effects. Acta Oncol. 2003;42(4):294_303. 62. Kim MH, Albertsson P, Xue Y, Nannmark U, Kitson RP, Goldfarb RH. _Expression of neutrophil collagenase (MMP_8) in Jurkat T leukemia cells and its role in invasion. Anticancer Res. 2001 Jan_Feb;21(1A):45_50. 63. Gustavsson ML, Johnsson C, Albertsson P, Lukes D, Steen LM, Johansson BR, Mjörnstedt L, Norrby J, Tufveson G, Olausson M. _Characterization of Forssman and other antigen/antibody systems in vascularized mouse heart to rat xenotransplantation. Scand J Immunol. 2001 Feb;53(2):121_31 64. Jonges LE, Albertsson P, van Vlierberghe RL, Ensink NG, Johansson BR, van de Velde CJ, Fleuren GJ, Nannmark U, Kuppen PJ. _The phenotypic heterogeneity of human natural killer cells: presence of at least 48 different subsets in the peripheral blood. Scand J Immunol. 2001 Feb;53(2):103_10 65. Nannmark U, Hokland ME, Agger R, Christiansen M, Kjaergaard J, Goldfarb RH, Bagge U, Unger M, Johansson BR, Albertsson PA and Basse PH. _Tumor blood supply and tumor localization by adoptively transferred IL_2 activated natural killer cells. In Vivo. 2000 Sep_Oct;14(5):651_8. 66. Kim MH, Albertsson P, Xue Y, Kitson RP, Nannmark U, Goldfarb RH. _Expression of matrix metalloproteinases and their inhibitors by rat NK cells: inhibition of their expression by genistein. In Vivo. 2000 Sep_Oct;14(5):557_64. 67. Chuang SS, Kim MH, Johnson LA, Albertsson P, Kitson RP, Nannmark U, Goldfarb RH, Mathew PA. _2B4 stimulation of YT cells induces natural killer cell cytolytic function and invasiveness. Immunology. 2000 Jul;100(3):378_83. 68. Kim MH, Kitson RP, Albertsson P, Nannmark U, Basse PH, Kuppen PJ, Hokland ME, Goldfarb RH. _Secreted and membrane_associated matrix metalloproteinases of IL_2_activated NK cells and their inhibitors. J Immunol. 2000 Jun1;164(11):5883_9. 69. Albertsson P, Kim MH, Jonges LE, Kitson RP, Kuppen PJ, Johansson BR, Nannmark U, Goldfarb RH. _Matrix metalloproteinases of human NK cells. In Vivo. 2000;14(1):269_76. 70. Goldfarb RH, Albertsson P, Nannmark U, Kitson RP. _Cytolytic activities of IL_2 activated NK cells from MMTV/v_Ha_ras transgenic oncomice during tumor progression. In Vivo. 1998;12(6):589_92. 71. Kitson RP, Appasamy PM, Nannmark U, Albertsson P, Gabauer MK, Goldfarb RH. _Matrix metalloproteinases produced by rat IL_2_activated NK cells. J Immunol. 1998 1;160(9):4248_53. 72. Johansson BR, Unger ML, Albertsson P, Casselbrant A, Nannmark U, Hokland M. _Infiltration and lysis of tumour cell aggregates by adherent interleukin_2_activated natural killer cells is distinct from specific cytolysis. Nat Immun. 1996_1997;15(2_3):87_97. 73. Albertsson PA, Nannmark U, Johansson BR. _Melanoma cell destruction in the micro_vasculature of perfused hearts is reduced by pretreatment with vitamin E. Clin Exp Metastasis. 1995 Jul;13(4):269_76. 74. Nordenskjöld A, Dar H, Albertsson P, Fornander T, Karlsson P, Skoog L, Stål O, Lindström L. _Progesteron receptor gene expression and immunohistochemistry as predictors of adjuvant tamoxifen benefit in estrogen receptor positive breast cancer. In: To predict results of breast cancer therapy. Anna Nordenskjöld. University of Gothenburg 20196. ISBN 978_91_7833_316_5 75. Per Albertsson. _Målriktad strålterapi på cellnivå. Svensk Onkologi Nr 5, 2017 pp 23_25. 76. Albertsson P, Björkander E, Hallqvist A, Liljegren A, Månsson C, Strandell A, Samuelsson O. _Positron emission tomography and computed tomographic imaging prior to radiotherapy for anal cancer [PET/CT inför strålbehandling av analcancer]. Göteborg: Västra Götalandsregionen, Sahlgrenska Universitetssjukhuset, HTA_centrum; 2016. Regional activity_based HTA 2016:87

77. Hallqvist A, Albertsson P, Björkander E, LiljegrenA, Månsson C, Strandell A, Samuelsson O. _Positron Emission Tomography and Computed Tomographic Imaging Prior to Radiotherapy for lung cancer [PET/CT inför strålbehandling av lungcancer] Göteborg: Västra Götalandsregionen, Sahlgrenska Universitetssjukhuset, HTA_centrum; 2016. Regional activity_based HTA 2016:88 78. Gustafsson_Lutz A, Bäck T, Aneheim E, Albertsson P, Press O, Hamlin D, Lindegren S. _Galactosylated, biotinylated and charge_modified polylysine: Evaluation as clearing agent for pretargeteing in cancer therapy and imaging. pp1_11. In: Development of targeted alpha_therapy with Bi_213 and At_211 for the treatment of disseminated cancer. Anna Gustafsson_Lutz. University of Gothenburg 2016. ISBN978_91_628_9720_8 79. Ragnar Hultborn, Per Albertsson _Strålterapi vid äggstockscancer Gyncancer den 20 november, 2013 http://gyncancer.se/2013/11/stralterapi_vid_aggstockscancer/ 80. Elgqvist J, Lindegren S and Albertsson P (2012). _Intraperitoneal radionuclide therapy: clinical and pre_clinical considerations. Book chapter 12, 29pp, in: Ovarian Cancer _ Clinical and Therapeutic Perspectives, Edit SA Farghaly, ISBN 979_953_307_674_3 81. Edsparr K, Cullin F, Barth H, Goldfarb RH, Basse PH, Lennernäs B, Kuppen PJK, Albertsson P. _The fractalkine (CX3CL1) chemokine stimulates NK_92 natural killer cell production of MMP_9. Pp1_7 In: Migration of Natural Killer cells –Matrixinteraction, locomotion and regulation of matrix metalloproteinases (MMPs) by IL_2 and chemokines. Karin Edsparr. University of Gothenburg 2009. ISBN 978_91_628_7829 82. Albertsson P, Lennernäs B, Norrby K. _On metronomic chemotherapy: modulation of angiogenesis mediated by VEGF_A. Oncology Review 2006;11/1:3_14 83. Attman PO, Hultström D, Johansson PL, Albertsson P, Hyllner M, Bengtsson A. _Medical guidelines: Erytropoietin (epo). Hälso_ och sjukvårdsavdelningen Västra Götalandsregionen 2004_06_27 84. Albertsson Per. _Matrix Metalloproteinases in Natural Killer Cells. Expression of MMPs, IL_2 activation, and killer cell interactions with Matrigel® and model tumours. Göteborg University, 2000, pp1_50. ISBN 91_628_4485_7

## Projects

Member of Study steering committee in SWANCA, a pan_Swedish proton vs photon phase_II study in analcarcinoma 2011 _ 2021: Leading Targeted alpha Therapy group at dept of Oncology and dept of Radiation physics University of Gothenburg (yearly budget approx 3 to 400,000 EUR) Holding grants, covering above budget, for this research from Swedisch Cancer Society, Swedish Research Socienty, Govremental funds (ALF), and Eurostars. 2021 _ Jan. 2023: leading clinical branch of above Research group.

## Memberships

2016 – 2023 Member of stear committee for gyneco_oncologic biobank 2014 – 2019 Member of (regional) Irradiation safety ethical board 2014 _ 2016 Member HTA_project 'PET in Radiation Therapy' 2008 _ 2009 Appointed member of Själland, Denmark, ColoRectal Working group

## Other Relevant Information

Peer reviewer: > 20 Journals Grant reviewer: 2021_ongoing _SwedishCancerSociety (Cancerfonden) PkE Radiationtherapy, radiao_ biology, imaging diagnostic. 2015 _ 2021 _Stockholm lcounty; ALF_senior research positions 2021 _Swedish Research Counsil (VR, Vetenskapsrådet), MH_08A 2008 _ 2013 _Stockholm county; ALF_grants Cancer 2019 _INSERM, France: Expert evaluation within, "Plan Cancer 2014_ 2019": 2020 2021 _External Expert radiation therapy/oncology for European Cooperation in Science and Technology COST: _Call OC2020_1. (x2 applications) _Call OC2021_1. (x3 applications) 2013 ongoing: Board Member: Jubileum Klinikens Cancer Forskningsfond, JKCF (Alternate Board member). 2018 _ 2023 Jan: Aprit Biotech AB(non active), co_founder, board member 2018_21. Stock owner 2018 _ Jan. 2023.